Reducing the Risk of MACE in T2DM with GLP-1RAs: Real World Considerations to Personalize Therapy
Brought to you by:
Academy for Continued Healthcare Learning (ACHL)
In this series, Dr. John B. Buse, Dr. Kathleen Dungan, and Dr. Christian T. Ruff present patient cases and share their personal approaches to reducing the risk of cardiovascular disease in diabetic patients. Using real-world evidence, they review cardiovascular risk stratification, the efficacy and safety of GLP-1 RA and cardiovascular outcomes trials, and COVID-19 implications as they develop a comprehensive treatment plan for a patient with cardiovascular risk factors.